CDXS vs GEVO

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus 18. 6% for Codexis, Inc. (CDXS). Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gevo, Inc.

(GEVO) delivered a total return of -65. 2%, compared to -86. 7% for Codexis, Inc. (CDXS). Over 10 years, the gap is even starker: CDXS returned -19. 6% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gevo, Inc.

(GEVO) is the lower-risk stock at 1. 64β versus Codexis, Inc. 's 2. 31β — meaning CDXS is approximately 40% more volatile than GEVO relative to the S&P 500. On balance sheet safety, Gevo, Inc. (GEVO) carries a lower debt/equity ratio of 36% versus 145% for Codexis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus 18. 6% for Codexis, Inc. (CDXS). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to 43. 8% for Codexis, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gevo, Inc.

(GEVO) is the more profitable company, earning -21. 1% net margin versus -62. 5% for Codexis, Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -54. 5% for CDXS. At the gross margin level — before operating expenses — CDXS leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Gevo, Inc.

(GEVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Codexis, Inc. (CDXS) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GEVO: -98. 6%, CDXS: -19. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDXS (Healthcare) and GEVO (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.